# Sudan Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Sudan HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Sudan (SDN)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $759.0K
- Products: 25
- Buyer markets: 25
- Average CAGR: +19.0%
- Global sector size: $109.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $58.2B | $414.6K | $19.7B | +61.7% | 13 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $13.6B | $193.0 | $5.2B | +63.6% | 1 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $9.9 | $4.9B | +67.2% | 1 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $6.9B | $36.6K | $4.2B | -20.5% | 2 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $4.2B | $2.4K | $2.7B | -1.1% | 9 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $4.8B | $54.6K | $2.3B | +39.7% | 5 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $5.8B | $34.8K | $2.3B | -14.3% | 6 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $2.4B | $9.2K | $1.1B | -13.5% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $1.6B | $14.3 | $1.1B | +36.5% | 2 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $734.9M | $1.2 | $798.7M | -61.0% | 1 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $899.8M | $4.5 | $570.1M | +17.3% | 1 | +0.0% |
| HS 330290 - Odoriferous substances and mixtures: used as raw materials in industries other than the food or drink industries | $740.6M | $25.4K | $371.7M | -43.9% | 1 | +0.0% |
| HS 330590 - Hair preparations: n.e.s. in heading no. 3305 | $467.9M | $661.5 | $357.9M | -20.1% | 1 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $813.9M | $16.4K | $326.1M | +29.8% | 3 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $792.7M | $11.4 | $301.3M | -20.2% | 2 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $1.0B | $66.9K | $281.1M | -4.1% | 1 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $639.7M | $80.2 | $261.4M | +20.3% | 1 | +0.0% |
| HS 294200 - Organic compounds: n.e.s. in chapter 29 | $198.7M | $95.8K | $175.1M | -9.8% | 1 | +0.0% |
| HS 280110 - Chlorine | $213.4M | $11.4 | $166.9M | +10.0% | 1 | +0.0% |
| HS 330749 - Perfumes and deodorizors: perfuming or deodorizing preparations for rooms, (excluding those which operate by burning) | $139.5M | $92.6 | $102.9M | -68.0% | 1 | +0.0% |
| HS 281122 - Silicon dioxide | $99.6M | $862.5 | $72.7M | +166.5% | 1 | +0.0% |
| HS 300691 - Pharmaceutical goods: appliances identifiable for ostomy use | $289.8M | $1.2 | $64.5M | -7.6% | 1 | +0.0% |
| HS 300310 - Medicaments: containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) | $44.5M | $2.2 | $64.4M | +2.3% | 1 | +0.0% |
| HS 300219 - Blood, human or animal, antisera, other blood fractions and immunological products: n.e.c. in heading 3002.1 | $145.3M | $1.9 | $60.4M | +55.4% | 1 | +0.0% |
| HS 340399 - Lubricating preparations: other than for the treatment of textile and similar materials, not containing petroleum oils or oils obtained from bituminous minerals | $150.7M | $557.9 | $47.1M | +23.0% | 1 | +0.0% |

## Best markets

- Netherlands (NLD): $18.6B calculated opportunity across 10 products.
- Canada (CAN): $6.7B calculated opportunity across 7 products.
- Germany (DEU): $5.8B calculated opportunity across 3 products.
- Ireland (IRL): $3.4B calculated opportunity across 2 products.
- China (CHN): $3.1B calculated opportunity across 3 products.
- Republic of Korea (KOR): $1.7B calculated opportunity across 3 products.
- India (IND): $1.7B calculated opportunity across 5 products.
- United Arab Emirates (ARE): $1.4B calculated opportunity across 5 products.
- France (FRA): $1.1B calculated opportunity across 4 products.
- Singapore (SGP): $1.1B calculated opportunity across 1 products.
- Australia (AUS): $537.0M calculated opportunity across 2 products.
- Kuwait (KWT): $365.4M calculated opportunity across 2 products.

## Growth stars

- HS 281122: +166.5% average CAGR, $72.7M calculated opportunity.
- HS 300214: +67.2% average CAGR, $4.9B calculated opportunity.
- HS 300215: +63.6% average CAGR, $5.2B calculated opportunity.
- HS 300490: +61.7% average CAGR, $19.7B calculated opportunity.
- HS 300219: +55.4% average CAGR, $60.4M calculated opportunity.
- HS 382200: +39.7% average CAGR, $2.3B calculated opportunity.
- HS 300220: +36.5% average CAGR, $1.1B calculated opportunity.
- HS 330210: +29.8% average CAGR, $326.1M calculated opportunity.
- HS 340399: +23.0% average CAGR, $47.1M calculated opportunity.
- HS 300212: +20.3% average CAGR, $261.4M calculated opportunity.

## Diversification opportunities

- HS 300490: 13 buyer markets, $19.7B calculated opportunity.
- HS 300290: 9 buyer markets, $2.7B calculated opportunity.
- HS 330499: 6 buyer markets, $2.3B calculated opportunity.
- HS 382200: 5 buyer markets, $2.3B calculated opportunity.
- HS 330300: 3 buyer markets, $1.1B calculated opportunity.
- HS 330210: 3 buyer markets, $326.1M calculated opportunity.
- HS 382499: 2 buyer markets, $4.2B calculated opportunity.
- HS 300220: 2 buyer markets, $1.1B calculated opportunity.
- HS 293499: 2 buyer markets, $301.3M calculated opportunity.
- HS 300215: 1 buyer markets, $5.2B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.